Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Judy Hertel
Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison
European Journal of Haematology
Medicine
Hematology
Related publications
Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Single-Agent Thalidomide for Treatment of First Relapse Following High-Dose Chemotherapy in Patients With Multiple Myeloma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib
British Journal of Haematology
Hematology
Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma
European Journal of Medical Research
Medicine
Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma
Case Reports in Hematology
Efficacy of Subcutaneous Bortezomib in the Management of Patients With Multiple Myeloma or Relapsed Mantle Cell Lymphoma
Clinical Medicine Insights: Therapeutics
Medicine
Pharmacology
Pharmaceutical Science
Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Blood Cancer Journal
Oncology
Hematology
Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study
Research in Oncology
